The drug-related provisions of the Biden-era law led to a decline in cost-related drug nonadherence among Medicare enrollees in the program's first year. The study used a difference-in-differences quasi-experimental design. The law, known as the Inflation Reduction Act of 2022, introduced changes to lower drug prices and out-of-pocket costs in Medicare. Starting in 2023, Medicare beneficiaries do not pay for vaccines. By 2025, the out-of-pocket cost of prescriptions is capped at $2,000 per year. The study showed an improvement in medication adherence, particularly for insulin. Medication nonadherence is associated with worse health outcomes and higher costs.[1][2][3]